SWEDISH ORPHAN BIOVITRUM AB (1SOBI.MI) Stock Price & Overview
BIT:1SOBI • SE0000872095
Current stock price
The current stock price of 1SOBI.MI is 35.98 EUR. Today 1SOBI.MI is up by 2.92%.
1SOBI.MI Key Statistics
- Market Cap
- 12.86B
- P/E
- 299.83
- Fwd P/E
- 19.85
- EPS (TTM)
- 0.12
- Dividend Yield
- N/A
1SOBI.MI Stock Performance
1SOBI.MI Stock Chart
1SOBI.MI Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to 1SOBI.MI.
1SOBI.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 1SOBI.MI. While 1SOBI.MI has a great profitability rating, there are some minor concerns on its financial health.
1SOBI.MI Earnings
On February 5, 2026 1SOBI.MI reported an EPS of 5.34 and a revenue of 7.82B. The company beat EPS expectations (24.59% surprise) and missed revenue expectations (-4.6% surprise).
1SOBI.MI Forecast & Estimates
18 analysts have analysed 1SOBI.MI and the average price target is 41.26 EUR. This implies a price increase of 14.66% is expected in the next year compared to the current price of 35.98.
For the next year, analysts expect an EPS growth of 1404.9% and a revenue growth 11.39% for 1SOBI.MI
1SOBI.MI Groups
Sector & Classification
1SOBI.MI Financial Highlights
Over the last trailing twelve months 1SOBI.MI reported a non-GAAP Earnings per Share(EPS) of 0.12. The EPS decreased by -88.99% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 1.69% | ||
| ROA | 0.71% | ||
| ROE | 1.27% | ||
| Debt/Equity | 0.14 |
1SOBI.MI Ownership
1SOBI.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 24.48 | 37.118B | ||
| 1AE | ARGENX SE | 24.67 | 37.043B | ||
| 22UA | BIONTECH SE-ADR | N/A | 19.08B | ||
| ABVX | ABIVAX SA | N/A | 8.492B | ||
| 2X1 | ABIVAX SA | N/A | 8.477B | ||
| GXE | GALAPAGOS NV | N/A | 1.877B | ||
| GLPG | GALAPAGOS NV | N/A | 1.854B | ||
| NANO | NANOBIOTIX | N/A | 1.365B | ||
| 6IV | INVENTIVA SA | N/A | 1.087B | ||
| IVA | INVENTIVA SA | N/A | 1.059B | ||
| PHIL | PHILOGEN SPA | 18.61 | 663.748M | ||
| XUP | GENFIT | 917.65 | 468.027M | ||
| GNFT | GENFIT | 889.51 | 440.026M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1SOBI.MI
Company Profile
Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. The company is headquartered in Stockholm, Stockholm and currently employs 1,888 full-time employees. The company went IPO on 2006-09-15. The firm develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The firm has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.
Company Info
IPO: 2006-09-15
SWEDISH ORPHAN BIOVITRUM AB
Norra Stationsgatan 93A
Stockholm STOCKHOLM SE
Employees: 1888
Phone: 4686972000
SWEDISH ORPHAN BIOVITRUM AB / 1SOBI.MI FAQ
What does SWEDISH ORPHAN BIOVITRUM AB do?
Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. The company is headquartered in Stockholm, Stockholm and currently employs 1,888 full-time employees. The company went IPO on 2006-09-15. The firm develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The firm has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others.
What is the stock price of SWEDISH ORPHAN BIOVITRUM AB today?
The current stock price of 1SOBI.MI is 35.98 EUR. The price increased by 2.92% in the last trading session.
Does 1SOBI stock pay dividends?
1SOBI.MI does not pay a dividend.
What is the ChartMill rating of SWEDISH ORPHAN BIOVITRUM AB stock?
1SOBI.MI has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What do analysts say about SWEDISH ORPHAN BIOVITRUM AB (1SOBI.MI) stock?
18 analysts have analysed 1SOBI.MI and the average price target is 41.26 EUR. This implies a price increase of 14.66% is expected in the next year compared to the current price of 35.98.
Can you provide the growth outlook for SWEDISH ORPHAN BIOVITRUM AB?
The Revenue of SWEDISH ORPHAN BIOVITRUM AB (1SOBI.MI) is expected to grow by 11.39% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of 1SOBI stock?
SWEDISH ORPHAN BIOVITRUM AB (1SOBI.MI) has a market capitalization of 12.86B EUR. This makes 1SOBI.MI a Large Cap stock.